In order to enable the advent of personalized medicine, we need solid in vitro models, taking into account the 3D microenvironment of the tumor, the human component, and the vasculature, to test both the toxicity and efficacy of new molecules. Today, the drug screenings are performed on 3D cell lines models and Patient-Derived Xenografts models. These models are not able to recapitulate the whole tumor microenvironment and vasculature, with hopeless return to the patient. Here, we propose our in vitro model, based on Patient-Derived Organoids, in a vascularized 3D environment, including mesenchymal stem cells. We believe that this will greatly contribute to the development of personalized medicine, since we are working on both healthy tissue (toxicity) and tumor tissue (efficacy). The second step of this model will be the integration of immune cells based on recent discoveries.
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
Tel.: +1 703 830 6300
Fax: +1 703 830 2300 firstname.lastname@example.org
(Corporate matters and books only) IOS Press c/o Accucoms US, Inc.
For North America Sales and Customer Service
West Point Commons
Lansdale PA 19446
Tel.: +1 866 855 8967
Fax: +1 215 660 5042 email@example.com